Chair: Hiddo Lambers Heerspink (NLD)
|15:30 – 15:35||Chair welcome and introductions||Hiddo Lambers Heerspink (NLD)|
|15:35 – 15:55||Cellular energetics and the positive impact of SGLT2 inhibition||Esther Phielix (NLD)|
|15:55 – 16:15||The science supporting SGLT2 inhibitors renal benefits||Hiddo Lambers Heerspink (NLD)|
|16:15 – 16:35||The underlying mechanisms of SGLT2 inhibitors across the ejection fraction spectrum||Kieran Docherty (UK)|
|16:35 – 16:55||SGLT2 inhibitors: Where do we go from here?||All faculty|
|16:55 – 17:00||Summary and close||Hiddo Lambers Heerspink (NLD)|
Disclaimer: This non-promotional symposium is organized and funded by AstraZeneca for healthcare professionals only.